News
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
Eli Lilly and Company has announced a definitive agreement to acquire Scorpion Therapeutics' PI3Kα inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3Kα...
Gilead and LEO Pharma to accelerate development of oral STAT6 program with potential in...
Gilead Sciences and LEO Pharma have announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer...
Newron and Myung In Pharm announce license agreement for schizophrenia treatment in South Korea
Newron Pharmaceuticals, a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, and Myung In...
